USPTO trademark

JEMIQTA

RegisteredUSPTOWord markClass 5Class 10

"JEMIQTA" is a word mark owned by H. Lundbeck A/S, filed at the USPTO on July 14, 2025. It is registered and covers classes 5 and 10.

Official USPTO record
JEMIQTA trademark as filed
As filed with the USPTO
Status
Registered
Since February 10, 2026
Filed
July 14, 2025
Registered
February 10, 2026
Priority date
July 1, 2025
Claimed from Denmark
Application no.
99281818
Registration no.
8137171
Office
USPTO
United States Patent and Trademark Office
Mark type
Word mark
2 classes
Ownership

Who owns JEMIQTA

The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.

Goods and services

What the mark covers

The products and services JEMIQTA is filed for, grouped by Nice class.

  • Sanitary preparations for medical purposes; dietetic preparations for medical use; vaccines; pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases of, generated from and affecting the central nervous system; pharmaceutical preparations and substances for the treatment of central nervous system disorders; central nervous system stimulants; pharmaceutical preparations and substances for the diagnosis, prevention and treatment of psychiatric, neurological, neurohormonal, neurogenetic, neuroendocrinological and autoimmune diseases and disorders; pharmaceutical preparations and substances for diagnosis, prevention and treatment of dementia, Alzheimer's disease, depression, psychosis, anxiety, Lennox-Gastaut disease, epilepsy, Dravet Syndrome, Developmental and Epileptic Encephalopathy (DEE), alpha-synucleinopathies, Multiple System Atrophy (MSA), dementia with Lewy bodies, rapid eye movement (REM) sleep behavior syndrome, porphyria, Huntington's disease, insomnia, Parkinson's disease, sclerosis, multiple sclerosis, schizophrenia, bipolar disorder, cancer, pain, migraine, headache, Horton's headache, traumatic brain injury, post-traumatic brain injury, dizziness, seizures, stroke, cognitive impairment, cognitive disorders and diseases, mood disorders, falls, movement disorders and diseases, tremor, agitation, mania, aggression, autism, melancholia, Obsessive Compulsive Disorder (OCD), Tourette's syndrome, restlessness, akathisia, fatigue, somnolence, nausea, Cushing's disease, Adrenogenital syndrome (AGS), narcolepsy, Post-Traumatic Stress Disorder (PTSD), Attention Deficit Hyperactivity Disorder (ADHD), Progressive Supranuclear Palsy (PSP), Thyroid Associated Orbitopathy (TAO), Graves Orbitopathy, Hashimoto's Thyroiditis, alcoholism and addiction; diagnostic agents and preparations for medical purposes; chemical substances for diagnostic and medical purposes, namely, chemical reagents for medical use, diagnostic chemical reagents for medical purposes; medical diagnostic reagents

  • Medical apparatus, namely, infusion and injection devices for administering drugs; Medical syringes, intravenous bags sold empty for intravenous therapy, intravenous (IV) feeding tubes, intravenous (IV) infusion pumps, and intravenous (IV) catheters; injection devices for administering drugs, syringes and needles for injections and medical purposes; Apparatus and instruments for diagnostic purposes, namely, dosage management dispensers for administering medicines, incorporating downloadable and recorded software for medical information management for use in web-based physical and psychological examination and assessment of patients at a distance and at a clinic; Medical devices and instruments for use in the diagnosis, medicine administration, monitoring, assessment, control and examination of psychiatric, neurological, neurohormonal, neurogenetic, neuroendocrinological and autoimmune disorders and diseases; integrated medical systems comprising of medical instruments for diagnostics and examination of patients and downloadable software for processing patient intake and communications and information management, all for use in the examination and assessment of patients and clients; integrated medical systems comprised of medical instruments for treating central nervous system diseases and disorders and psychiatric, neurological, neurohormonal, neurogenetic, neuroendocrinological and autoimmune disorders and diseases, all for the purposes of management, measurement, monitoring, evaluation, control, collection, storage, transmission and examination of patient and client data and information; medical instruments, namely, devices for delivery and administering of medicines in the nature of infusion and injection devices and infusion pumps for providing medication administering information, guidance, and management

History

What has happened so far

Steps recorded by the USPTO, newest first.

  1. Notice of registration confirmation emailed
  2. Registered-principal register
  3. Official gazette publication confirmation e-mailed
  4. Published for opposition
  5. Notification of notice of publication e-mailed
  6. Approved for pub - principal register
  7. Teas/email correspondence entered
  8. Correspondence received in law office
  9. Teas response to office action received
  10. Notification of non-final action e-mailed

6 earlier steps on the official record.

FAQ

About JEMIQTA

Who owns the trademark "JEMIQTA"?

The USPTO trademark "JEMIQTA" (application 99281818) is owned by H. Lundbeck A/S.

What is the status of "JEMIQTA"?

Its status at the USPTO is: registered.

When was "JEMIQTA" registered?

It was registered on February 10, 2026.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull JEMIQTA and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

GET /v1/trademarks/{id}
ID=tm_019d2af6-d0b8-71d8-9562-09d8c3f3ca6c
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_019d2af6-d0b8-71d8-9562-09d8c3f3ca6c",
  "object": "trademark",
  "mark_text": "JEMIQTA",
  "status": {
    "primary": "active",
    "stage": "registered"
  },
  "office_code": "US",
  "application_number": "99281818",
  "filing_date": "2025-07-14",
  "nice_classes": [
    5,
    10
  ],
  "owners": [
    {
      "name": "H. Lundbeck A/S",
      "entity_id": "ent_019eb6fd-c6b8-7323-bcf8-455bb92dfb3d"
    }
  ]
}